Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALC NASDAQ:ENSC NASDAQ:GTBP NASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.86-1.4%$0.70$0.46▼$7.20$13.74M0.97318,112 shs143,611 shsENSCEnsysce Biosciences$0.28+3.0%$0.36$0.23▼$2.75$4.15M0.831.05 million shs1.46 million shsGTBPGT Biopharma$0.45-4.9%$0.40$0.26▼$3.85$16.90M0.861.70 million shs1.28 million shsQNTMQuantum Biopharma$3.64-1.6%$4.97$2.07▼$38.25$14.12M0.36454,854 shs94,988 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+0.35%-9.19%+32.40%+4.38%-49.42%ENSCEnsysce Biosciences+7.44%+6.68%-3.64%-43.18%-86.96%GTBPGT Biopharma+4.85%+10.23%+18.99%+7.92%-83.50%QNTMQuantum Biopharma-3.39%-8.64%-45.67%+54.81%-81.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$0.86-1.4%$0.70$0.46▼$7.20$13.74M0.97318,112 shs143,611 shsENSCEnsysce Biosciences$0.28+3.0%$0.36$0.23▼$2.75$4.15M0.831.05 million shs1.46 million shsGTBPGT Biopharma$0.45-4.9%$0.40$0.26▼$3.85$16.90M0.861.70 million shs1.28 million shsQNTMQuantum Biopharma$3.64-1.6%$4.97$2.07▼$38.25$14.12M0.36454,854 shs94,988 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+0.35%-9.19%+32.40%+4.38%-49.42%ENSCEnsysce Biosciences+7.44%+6.68%-3.64%-43.18%-86.96%GTBPGT Biopharma+4.85%+10.23%+18.99%+7.92%-83.50%QNTMQuantum Biopharma-3.39%-8.64%-45.67%+54.81%-81.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 2.00Hold$10.001,065.50% UpsideENSCEnsysce Biosciences 1.00SellN/AN/AGTBPGT Biopharma 1.00SellN/AN/AQNTMQuantum Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ENSC, QNTM, GTBP, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026ENSCEnsysce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026GTBPGT Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/AENSCEnsysce Biosciences$5.07M0.84N/AN/A$0.63 per share0.44GTBPGT BiopharmaN/AN/A$0.01 per share31.33$0.23 per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$1.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)ENSCEnsysce Biosciences-$10.18M-$3.35N/AN/AN/A-250.39%-766.45%-256.59%8/12/2026 (Estimated)GTBPGT Biopharma-$28.35M-$6.33N/AN/AN/AN/AN/A-102.03%8/13/2026 (Estimated)QNTMQuantum Biopharma-$26.17M-$8.25N/AN/AN/AN/A-941.54%-224.41%8/6/2026 (Estimated)Latest ENSC, QNTM, GTBP, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ENSCEnsysce Biosciences-$0.73-$0.52+$0.21-$0.52$1.00 million$0.96 million5/15/2026Q1 2026GTBPGT Biopharma-$0.08-$0.11-$0.03-$0.11N/AN/A3/30/2026Q4 2025ENSCEnsysce Biosciences-$1.26-$0.75+$0.51-$0.75$0.50 million$1.88 million3/26/2026Q4 2025QNTMQuantum Biopharma-$0.22-$0.71-$0.49-$0.71$2.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A1.611.61ENSCEnsysce BiosciencesN/A0.710.71GTBPGT BiopharmaN/A4.144.14QNTMQuantum BiopharmaN/A0.630.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/AENSCEnsysce Biosciences5.63%GTBPGT Biopharma8.15%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%ENSCEnsysce Biosciences2.80%GTBPGT Biopharma3.40%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3015.80 million9.23 millionNo DataENSCEnsysce Biosciences1015.37 million14.94 millionNot OptionableGTBPGT Biopharma836.06 million34.84 millionNo DataQNTMQuantum BiopharmaN/A3.82 million3.49 millionN/AENSC, QNTM, GTBP, and CALC HeadlinesRecent News About These CompaniesQuantum BioPharma (QNTM) Advances Proprietary Therapy for MS TreatmentJune 9, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire PodcastJune 3, 2026 | finance.yahoo.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.June 2, 2026 | globenewswire.comQuantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation CampaignsJune 2, 2026 | globenewswire.comQuantum BioPharma Provides Corporate UpdateJune 1, 2026 | globenewswire.comQuantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 20, 2026 | finance.yahoo.comQuantum BioPharma shares climb as multiple sclerosis imaging study advances (QNTM)May 18, 2026 | msn.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 18, 2026 | markets.businessinsider.comQuantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General HospitalMay 18, 2026 | globenewswire.comQuantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in ...May 7, 2026 | caledonianrecord.comCQuantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026May 7, 2026 | globenewswire.comQuantum BioPharma (QNTM) price target increased by 10.88% to 36.72April 28, 2026 | msn.comQuantum BioPharma Provides Corporate UpdateApril 27, 2026 | globenewswire.comQuantum BioPharma Ltd.April 24, 2026 | barrons.comQuantum BioPharma’s Unbuzzd Licensee Names New CEO to Drive U.S. Rollout of Clinically Backed Hangover BeverageApril 24, 2026 | theglobeandmail.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and ...April 24, 2026 | markets.businessinsider.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism AccelerantApril 22, 2026 | globenewswire.comComparing Quantum Biopharma (NASDAQ:QNTM) & Arcutis Biotherapeutics (NASDAQ:ARQT)April 19, 2026 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENSC, QNTM, GTBP, and CALC Company DescriptionsCalciMedica NASDAQ:CALC$0.86 -0.01 (-1.38%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.01 (+1.63%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Ensysce Biosciences NASDAQ:ENSC$0.28 +0.01 (+3.00%) Closing price 04:00 PM EasternExtended Trading$0.27 -0.01 (-2.88%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.GT Biopharma NASDAQ:GTBP$0.45 -0.02 (-4.91%) Closing price 04:00 PM EasternExtended Trading$0.45 +0.00 (+0.74%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Quantum Biopharma NASDAQ:QNTM$3.64 -0.06 (-1.62%) Closing price 04:00 PM EasternExtended Trading$3.63 -0.01 (-0.27%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
